Electricity is the currency of the brain

Harnessing the brain’s restorative power

Electricity is the new medicine

Mission & Vision

We’re advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.

Our CEO, Brent Vaughan speaks about the promise of neuromodulation to improve the lives of millions of Alzheimer’s patients.

Our Novel Platform

Introducing our novel platform for neurodegenerative disease

Our investigational medical device delivers non-invasive neuromodulation with the potential to improve outcomes in a range of neurodegenerative diseases, including Alzheimer’s disease.

Home platform card
Our Pipeline

Leveraging our platform across multiple neurodegenerative diseases.

Focus

CogTx-001

Alzheimer’s Disease

CogTx-002

Mild Cognitive Impairment

CogTx-003

Parkinson's Disease

CogTx-004

TBI-related Dementia

CogTx-005

Ischemic Stroke

CogTx-006

Multiple Sclerosis

Discovery

Preclinical

Early Clinical

Pivotal Clinical

In market

Latest News & Updates

Stay up to date

article placeholder
Ushering in a New Class of Disease-Modifying DTx
Healio media
Cognito Therapeutics, Aetion to partner on AI model that identifies AD patients
Fierce 15
Fierce Medtech's 2021 Fierce 15
article placeholder
Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment
Careers

Join our growing team

Clinical Affairs

Clinical Trial Manager

Remote

Design

Industrial Designer

Cambridge, MA

Engineering

Signal Processing Scientist/Engineer

Cambridge, MA